Results of treatment after relapse from high-dose chemotherapy in germ cell tumors

Journal of Clinical Oncology

Volumn 18, Issue 6, 2000, Pages 1181-1186

  Porcu, Pierluigi ^a   Bhatia, Sumeet ^a   Sharma, Matt ^a   Einhorn, Lawrence H ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; AZACITIDINE; BLEOMYCIN; CISPLATIN; DACTINOMYCIN; ETOPOSIDE; GEMCITABINE; IFOSFAMIDE; INTERLEUKIN 2; METHOTREXATE; PACLITAXEL; VINBLASTINE; VINCRISTINE;

ADOLESCENT; ADULT; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; DRUG MEGADOSE; GERM CELL TUMOR; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; TERATOMA; TREATMENT OUTCOME; YOLK SAC TUMOR;

EID: 0034018538     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2000.18.6.1181     Document Type: Article

References (27)

1. Nichols CR, Andersen J, Lazarus HM, et al: High-dose carboplatin and etoposide with autologous bone marrow transplantation in refractory germ cell cancer: An Eastern Cooperative Oncology Group protocol. J Clin Oncol 10:558-563, 1992
2. Broun ER Nichols CR, Gize G, et al: Tandem high-dose chemotherapy with autologous bone marrow transplantation for initial relapse of testicular germ cell cancer. Cancer 79:1605-1610, 1997
3. Einhorn LH: Salvage therapy for germ cell tumors. Semin Oncol 21:47-51, 1994 (suppl 7)
4. Sobecks RM, Vogelzang NJ: High-dose chemotherapy with autologous stem cell support for germ cell tumors: A critical review. Semin Oncol 26:106-118, 1999
5. International Germ Cell Cancer Collaborative Group: International germ cell consensus classification: A prognostic factor-based staging system for metastatic germ cell cancers. J Clin Oncol 15:594-603, 1997
6. Beyer J, Kramar A, Mandanas R, et al: High-dose chemotherapy as salvage treatment in germ-cell tumors: A multivariate analysis of prognostic variables. J Clin Oncol 14:2638-26445, 1996
7. Motzer RJ, Mazumdar M, Bosl GJ, et al: High-dose carboplatin, etposide and cyclophosphamide for patients with refractory germ cell tumors: Treatment results and prognostic factors for survival and toxicity. J Clin Oncol 14:1098-1105, 1996
8. Broun ER, Nichols CR, Kneebone P, et al: Long-term outcome of patients with relapsed and refractory germ cell tumors treated with high-dose chemotherapy and autologous bone marrow rescue. Ann Intern Med 117:124-128, 1992
9. Droz JP, Kramar A, Pico JL, et al: Prediction of long term response after high-dose chemotherapy with autologous bone marrow transplantation in the salvage treatment of non-seminomatous germ cell tumors. Eur J Cancer 29A:818-821, 1993
10. Beyer J, Kingreen D, Krause M, et al: Long term survival of patients with recurrent or refractory germ cell tumors after high-dose chemotherapy. Cancer 79:161-168, 1997
11. Rick O, Beyer J, Kingreen D, et al: High-dose chemotherapy in germ cell tumors: A large single center experience. Eur J Cancer 34:1883-1888, 1998
12. Murphy B, Breeden ES, Donohue JP, et al: Surgical salvage of chemorefractory germ cell tumors. J Clin Oncol 11:324-329, 1993
13. Shamash J, Asterling S, Oliver RTD: Salvage treatment for germ cell cancer after failed high-dose therapy. Ann Oncol 8:1387-1388, 1997 (letter)
14. Gerl A, Wilmanns W: Anti-tumor activity of paclitaxel after failure of high-dose chemotherapy in a patient with late relapse of a non-seminomatous germ cell tumor. Anticancer Drugs 7:716-718, 1996
15. Pont J, Bokemeyer C, Harstrick A, et al: Chemotherapy for germ cell tumors relapsing after high-dose chemotherapy and stem cell support: A retrospective multicenter study of the Austrian Study Group on Urologic Oncology. Ann Oncol 8:1229-1234, 1997
16. Cooper MA, Einhorn LH: Maintenance chemotherapy with daily oral VP16 following salvage therapy in patients with germ cell tumors. J Clin Oncol 13:1167-1169, 1995
17. Miller JC, Einhorn LH: Phase II study of daily oral etoposide in refractory germ cell tumors. Semin Oncol 17:36-39, 1990
18. Sleven ML, Clark PI, Joel SP, et al: A randomized trial to evaluate the effect of schedule on the activity of etoposide in small cell lung cancer. J Clin Oncol 7:1333-1340, 1989
19. Greco FA, Johnson DH, Hainsworth JD: Chronic oral etoposide. Cancer 67:303-309, 1991
20. Einhorn LH, Stender MJ, Williams SD: Phase II trial of gemcitabine in refractory germ cell tumors. J Clin Oncol 17:509-511, 1999
21. Bokemeyer C, Gerl A, Schoffski O, et al: Gemcitabine in patients with relapsed or cisplatin-refractory testicular cancer. J Clin Oncol 17:512-516, 1999
22. Bokemeyer C, Beyer J, Metzner B, et al: Phase II study of paclitaxel in patients with relapsed or cisplatin-refractory testicular cancer. Ann Oncol 7:31-34, 1997
23. Motzer RJ, Bajorin DF, Schwartz LH, et al: Phase II trial of paclitaxel shows antitumor activity in patients with previously treated germ cell tumors. J Clin Oncol 12:2277-2283, 1994
24. Nasario A, Amato RJ, Hutchinson LL, et al: Paclitaxel in extensively pre-treated non-seminomatous germ cell tumors. Urol Oncol 1:184-187, 1995
25. Motzer RJ: Paclitaxel in salvage therapy for germ cell tumors. Semin Oncol 24:83-85, 1997 (suppl 15)
26. Sandler AB, Cristou A, Fox S, et al: A phase II trial of paclitaxel in refractory germ cell tumors. Cancer 82:1381-1386, 1998
27. Baniel J, Foster RS, Gonin R, et al: Late relapses of testicular cancer. J Clin Oncol 13:1170-1176, 1995